November 9, 2018

CT adds new condition for medical pot program

PHOTO | Flickr via Dank Depot
PHOTO | Flickr via Dank Depot

The legislature's Regulations Review Committee has greelit another condition for Connecticut's medical marijuana program, according to the state Department of Consumer Protection (DCP).

DCP, which oversees Connecticut's medical pot program, said chronic neuropathic pain from degenerative spinal disorders was added Wednesday to a list of 31 conditions approved for adults and eight for patients under 18.

Also Wednesday, the committee updated the medication Epidiolex, also known as cannabidol (CBD), as a Schedule V medication. The naturally occurring cannabinoid is consumed orally to combat rare, severe types of seizure disorders, and was approved by the Food and Drug Administration (FDA) in June.

The new regulations will take effect when DCP submits them to the Secretary of the State's office, who will post them online.

"These updates to the regulations mean that more patients with severe debilitating conditions will have additional options for medical treatment," DCP Commissioner Michelle H. Seagull said in a statement Thursday.

Connecticut's medical marijuana program currently has 29,543 patients, 1,000 certified prescribers and nine dispensaries.

In recent months, DCP has launched a database listing medical marijuana brands registered with the state and added eight new conditions to the program.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Should UConn build a $45 million ice rink in Storrs for its men’s and women’s hockey teams?<>
Most Popular on Facebook
Copyright 2017 New England Business Media